Accession Number : AD1005298


Title :   Therapeutic and Imaging Applications of Dopamine Receptors in Breast Cancer


Descriptive Note : Technical Report,01 Sep 2014,31 Aug 2015


Corporate Author : University of Cincinnati Cincinnati United States


Personal Author(s) : Ben-Jonathan,Nira


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1005298.pdf


Report Date : 01 Sep 2015


Pagination or Media Count : 18


Abstract : Patients with advanced breast cancer either do not respond to anti-hormonal therapy or develop resistance to chemotherapy,providing major incentives to seek novel therapies that circumvent these drawbacks. Dopamine (DA) is a catecholamine which acts as a neurotransmitter in the brain and as a hormone in the periphery. DA binds to five receptors, D2-like (D2, D3 and D4)and D1-like (D1 and D5). Our data show that D1R is overexpressed in breast carcinomas while adjacent normal breast tissue is D1R-negative. Fenoldopam, a potent D1R agonist, was highly effective in suppressing xenograft growth in mice, by increasing both apoptosis and necrosis. An imaging system for detecting D1R-expressing breast tumors has been developed,albeit it requires additional improvements. These data suggest that D1R analysis in tumor biopsies could serve as a prognostic biomarker for advanced breast cancer. Moreover, Fenoldopam, an FDA approved, selective D1R agonist which does not penetrate the brain, should be exploited as a novel therapeutic agent in patients who do not respond to standard of care therapy.


Descriptors :   breast cancer , cancer research , Dopamine , neoplasms , apoptosis , detectors , biological markers , therapeutics , ANTINEOPLASTIC AGENTS , POSITRON EMISSION TOMOGRAPHY , DIAGNOSTIC IMAGING


Distribution Statement : APPROVED FOR PUBLIC RELEASE